BigHat Biosciences and Lilly collaborate to advance AI-driven antibody therapeutics

CAR-T Digest - August 2020

17 Apr 2025: BigHat Biosciences and Lilly collaborate to advance AI-driven antibody therapeutics

BigHat Biosciences has partnered with Eli Lilly to develop next-generation antibody therapeutics using BigHat’s AI/ML-powered Milliner platform and Lilly’s drug discovery expertise
The collaboration focuses on up to two antibody programs aiming to design antibodies with improved functionality and biophysical properties for treating chronic diseases
BigHat retains full global rights to its programs, including its next-generation ADC for gastrointestinal cancers, which is expected to enter clinical trials in 2026
Lilly will support BigHat’s development efforts through its Catalyze360 initiative and will also make an equity investment in the company
This partnership aligns with BigHat’s strategy to form strategic collaborations while progressing its own pipeline in oncology and immunology, including novel ADCs and T-cell engagers